**PTX-200 PHASE 1B/2 CLINICAL TRIAL UPDATE**

- *Novel cancer drug PTX-200 shows evidence of safety and antitumor activity when combined with weekly paclitaxel in advanced cancer patients*
- *Expansion Phase enrollment to shortly commence at Montefiore Medical Center*
- *Moffitt Cancer Centre will now join the study under lead investigator Dr Heather Han*

**Melbourne, Australia – 26 August 2015** – Clinical stage oncology company Prescient Therapeutics (ASX: PTX), today announced encouraging early clinical data arising from their ongoing Phase 1b/2 clinical study of novel cancer drug PTX-200 trial in breast, lung and esophageal cancer.

The study is currently being conducted as an Investigator Sponsored Trial (IST) under the lead of Professor Joseph Sparano, Professor of Medicine & Obstetrics, Gynecology, and Women's Health at Montefiore Medical Center and the Albert Einstein College of Medicine and Cancer Center, and has been partially funded by the U.S. National Cancer Institute.

Professor Joseph Sparano said PTX-200 was a highly promising oncology compound and prior studies had yet to fully exploit its potential anticancer activity “In the phase 2 study that will begin upon completion of the expansion cohort, we will determine the pathologic complete response rate after PTX-200 plus paclitaxel therapy in patients with locally advanced breast cancer – this model has been used in other trials to identify promising new agents and advance their development in a rapid and efficient manner.”

To date 14 patients with advanced cancer have been treated with Prescient’s PTX-200 in combination with weekly paclitaxel chemotherapy in this Phase 1 study with evidence of antitumor activity noted. PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many tumors, and contributes to paclitaxel resistance. Dose escalation of PTX-200 has proceeded to the third and final dose level, and the researchers will soon initiate an expansion cohort in 12 patients at the recommended phase II dose of PTX-200 to better characterize the safety profile of the combination.

Prescient’s CEO, Dr Rob Crombie said “One must always be cautious in interpreting data from such small patient numbers, however we are sufficiently encouraged that we are positioned to move into expansion phase of the study. To this end, we are pleased to advise that one of the world’s largest cancer centres, the Moffitt Cancer Center, will now join the study under the direction of lead Investigator Dr Heather Han.”
A previous Phase 1 clinical study using PTX-200 as a single agent carried out at the M.D. Anderson and Moffitt Cancer Centers in patients with advanced leukemia showed stabilization of disease in 17 of 32 patients after a single round of treatment with 3 patients showing a decrease in the number of leukemic blast cells with 1 patient showing a marked reduction in leukocytosis and spleen size.

An additional Phase 1b/2 clinical trial of PTX-200 is underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt Cancer Centre, and Prescient is planning a Phase 1b/2 trial evaluating PTX-200 in combination with cytarabine in acute leukemia, a follow on from the Phase 1 study that has already completed.

**About Prescient Therapeutics**
Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1-2 study of PTX-200 plus paclitaxel in breast cancer at the prestigious Montefiore Cancer Center in New York. The second is also a Phase 1b/2 trial in patients with recurrent or persistent platinum resistant ovarian cancer at Florida’s Moffitt Cancer Center. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient’s second novel drug candidate, PTX-100, is a first in class compound with the ability to block important cancer-causing proteins such as Ral and Rho, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

**Further Enquiries:**

**Dr Robert Crombie**
Managing Director
+61 (0) 3 9982 4563

**Rudi Michelson**
Monsoon Communications
+61 (0) 3 9620 3333